204 related articles for article (PubMed ID: 30291488)
21. Circulating Clusterin Levels and Cancer Risk: A Systematic Review and Meta-Analysis.
Beheshti Namdar A; Kabiri M; Mosanan Mozaffari H; Aminifar E; Mehrad-Majd H
Cancer Control; 2022; 29():10732748211038437. PubMed ID: 35465749
[TBL] [Abstract][Full Text] [Related]
22. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
[TBL] [Abstract][Full Text] [Related]
23. Single Nucleotide Polymorphism rs11136000 of CLU Gene (Clusterin, ApoJ) and the Risk of Late-Onset Alzheimer's Disease in a Central European Population.
Balcar VJ; Zeman T; Janout V; Janoutová J; Lochman J; Šerý O
Neurochem Res; 2021 Feb; 46(2):411-422. PubMed ID: 33206315
[TBL] [Abstract][Full Text] [Related]
24. Metabolic Syndrome, Mild Cognitive Impairment, and Dementia: A Meta-Analysis of Longitudinal Studies.
Atti AR; Valente S; Iodice A; Caramella I; Ferrari B; Albert U; Mandelli L; De Ronchi D
Am J Geriatr Psychiatry; 2019 Jun; 27(6):625-637. PubMed ID: 30917904
[TBL] [Abstract][Full Text] [Related]
25. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
[TBL] [Abstract][Full Text] [Related]
26. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
[TBL] [Abstract][Full Text] [Related]
27. Can clock drawing differentiate Alzheimer's disease from other dementias?
Tan LP; Herrmann N; Mainland BJ; Shulman K
Int Psychogeriatr; 2015 Oct; 27(10):1649-60. PubMed ID: 26138809
[TBL] [Abstract][Full Text] [Related]
28. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia.
Olsson B; Hertze J; Lautner R; Zetterberg H; Nägga K; Höglund K; Basun H; Annas P; Lannfelt L; Andreasen N; Minthon L; Blennow K; Hansson O
J Alzheimers Dis; 2013; 33(1):45-53. PubMed ID: 22890100
[TBL] [Abstract][Full Text] [Related]
29. Immunity factor contributes to altered brain functional networks in individuals at risk for Alzheimer's disease: Neuroimaging-genetic evidence.
Bai F; Shi Y; Yuan Y; Xie C; Zhang Z
Brain Behav Immun; 2016 Aug; 56():84-95. PubMed ID: 26899953
[TBL] [Abstract][Full Text] [Related]
30. Brain clusterin protein isoforms and mitochondrial localization.
Herring SK; Moon HJ; Rawal P; Chhibber A; Zhao L
Elife; 2019 Nov; 8():. PubMed ID: 31738162
[TBL] [Abstract][Full Text] [Related]
31. Age of Symptom Onset and Longitudinal Course of Sporadic Alzheimer's Disease, Frontotemporal Dementia, and Vascular Dementia: A Systematic Review and Meta-Analysis.
Day S; Roberts S; Launder NH; Goh AMY; Draper B; Bahar-Fuchs A; Loi SM; Laver K; Withall A; Cations M
J Alzheimers Dis; 2022; 85(4):1819-1833. PubMed ID: 34958038
[TBL] [Abstract][Full Text] [Related]
32. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
[TBL] [Abstract][Full Text] [Related]
33. Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis.
Anstey KJ; Ashby-Mitchell K; Peters R
J Alzheimers Dis; 2017; 56(1):215-228. PubMed ID: 27911314
[TBL] [Abstract][Full Text] [Related]
34. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
[TBL] [Abstract][Full Text] [Related]
35. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
[TBL] [Abstract][Full Text] [Related]
36. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.
Petrou M; Dwamena BA; Foerster BR; MacEachern MP; Bohnen NI; Müller ML; Albin RL; Frey KA
Mov Disord; 2015 Jun; 30(7):928-35. PubMed ID: 25879534
[TBL] [Abstract][Full Text] [Related]
37. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
McCleery J; Morgan S; Bradley KM; Noel-Storr AH; Ansorge O; Hyde C
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010633. PubMed ID: 25632881
[TBL] [Abstract][Full Text] [Related]
38. Direct Interaction of Selenoprotein R with Clusterin and Its Possible Role in Alzheimer's Disease.
Chen P; Wang C; Ma X; Zhang Y; Liu Q; Qiu S; Liu Q; Tian J; Ni J
PLoS One; 2013; 8(6):e66384. PubMed ID: 23805218
[TBL] [Abstract][Full Text] [Related]
39. 1H MR spectroscopy in common dementias.
Kantarci K; Petersen RC; Boeve BF; Knopman DS; Tang-Wai DF; O'Brien PC; Weigand SD; Edland SD; Smith GE; Ivnik RJ; Ferman TJ; Tangalos EG; Jack CR
Neurology; 2004 Oct; 63(8):1393-8. PubMed ID: 15505154
[TBL] [Abstract][Full Text] [Related]
40. Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort.
Kleipool EEF; Trappenburg MC; Rhodius-Meester HFM; Lemstra AW; van der Flier WM; Peters MJL; Muller M
J Alzheimers Dis; 2019; 71(1):317-325. PubMed ID: 31381517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
